Hermetica Superfood Encyclopedia
The Short Answer
Bifidobacterium longum subsp. infantis is a specialized probiotic bacterium that colonizes the infant gut by efficiently metabolizing human milk oligosaccharides (HMOs), producing beneficial short-chain fatty acids (SCFAs) and bacteriocins. This action helps establish a healthy microbiome, modulate immune responses, and reduce systemic inflammation.
CategoryProbiotic & Fiber
GroupFermented/Probiotic
Evidence LevelModerate
Primary Keywordbifidobacterium longum subspecies infantis benefits
Synergy Pairings4
Bifidobacterium Longum Subspecies Infantis — botanical close-up
Health Benefits
Establishes a healthy gut microbiome in infants by efficiently metabolizing human milk oligosaccharides (HMOs).
Enhances immune system development and reduces the risk of infections in early life.
Reduces systemic inflammation and supports regulatory immune balance through short-chain fatty acid (SCFA) production.
Improves symptoms of irritable bowel syndrome (IBS), diarrhea, and gut permeability in adults.
Promotes nutrient absorption and supports the uptake of essential vitamins and minerals.
Protects against pathogenic bacteria and strengthens the gut barrier function
Origin & History
Natural habitat
Bifidobacterium longum subspecies infantis (B. infantis) is a gram-positive, lactic acid-producing probiotic bacterium native to the gut of breastfed infants. It uniquely metabolizes human milk oligosaccharides (HMOs), playing a critical role in early gut colonization, immune system development, and microbiome balance. This extensively studied strain offers significant anti-inflammatory and digestive health benefits, extending its efficacy to adults for immune modulation and gut integrity.
“Bifidobacterium longum subsp. infantis has been a natural component of the microbiota in breastfed infants for millennia, playing an unacknowledged but critical role in foundational immune health. Its specific identification and therapeutic application are modern developments, extending its use across the lifespan for its profound anti-inflammatory and gut-stabilizing effects.”Traditional Medicine
Scientific Research
Extensive clinical studies support the efficacy of B. infantis in establishing a healthy infant microbiome, programming immune responses, and reducing inflammatory gastrointestinal conditions. Research consistently documents its short-chain fatty acid (SCFA)-mediated mechanisms in both infant and adult health.
Preparation & Dosage
Traditional preparation
Supplements
Available in capsule, powder, or liquid forms, often included in infant formulas and specialized probiotic blends.
Dosage
Typically 1–10 billion CFUs (colony-forming units) daily, adjusted based on age, product formulation, and specific health needs.
Pairing
Often co-administered with prebiotics such as human milk oligosaccharides (HMOs) or galactooligosaccharides (GOS) for enhanced colonization and synergistic effects.
Application
Suitable for infants, children, and adults to support foundational gut and immune resilience.
Nutritional Profile
- Live Probiotic Cultures: Bifidobacterium longum subsp. infantis (1-10 billion CFUs per serving)
- Short-Chain Fatty Acids (SCFAs): Acetate and butyrate, supporting gut epithelial health and anti-inflammatory responses.
- Human Milk Oligosaccharide (HMO) Metabolizers: Enzymes that break down complex oligosaccharides.
- Immunomodulatory Compounds: Activate T-regulatory cells and reduce pro-inflammatory cytokines (e.g., IL-6, TNF-α).
How It Works
Mechanism of Action
B. infantis metabolizes human milk oligosaccharides (HMOs) via specific gene clusters encoding glycosyl hydrolases and ABC transporters, converting them into monosaccharides and beneficial short-chain fatty acids (SCFAs) like acetate and lactate. It also produces various bacteriocins (e.g., lanthipeptides, lasso peptides) that inhibit the growth of pathogenic bacteria, further supporting a healthy gut environment and immune modulation.
Clinical Evidence
Extensive clinical studies, including randomized controlled trials in infants, consistently demonstrate the efficacy of B. infantis. These studies, often involving cohorts from birth, show its ability to establish a healthy infant microbiome, program immune responses, and reduce inflammatory gastrointestinal conditions. Research also highlights its SCFA-mediated mechanisms in supporting overall gut health in both infant and adult populations.
Safety & Interactions
Bifidobacterium longum subsp. infantis is generally recognized as safe (GRAS), particularly for infants due to its natural presence in the gut microbiome. Side effects are rare and typically mild, such as temporary bloating or gas, especially when first introduced. No significant drug interactions have been widely reported, though caution is advised with immunocompromised individuals or those with central venous catheters. It is considered safe for use during pregnancy and lactation.
Synergy Stack
Hermetica Formulation Heuristic
Prebiotic matrix
Gut & Microbiome | Immune & Inflammation
Also Known As
Bifidobacterium longum subspecies infantisB. infantisBifidobacterium infantisInfant Bifidus
Frequently Asked Questions
What is B. infantis?
B. infantis is a specialized probiotic bacterium that naturally colonizes the infant gut, particularly in breastfed infants. It is adept at thriving by efficiently metabolizing human milk oligosaccharides (HMOs) into beneficial compounds.
How does B. infantis benefit infants?
It helps establish a healthy gut microbiome by utilizing HMOs, outcompeting harmful bacteria and producing short-chain fatty acids. This process supports immune system development, reduces inflammation, and lowers the risk of infections in early life.
What are Human Milk Oligosaccharides (HMOs) and why are they important to B. infantis?
HMOs are complex sugars found in breast milk that act as prebiotics, selectively feeding beneficial bacteria like B. infantis. B. infantis has unique genetic machinery to break down HMOs, making it particularly well-suited to the infant gut environment and giving it a competitive advantage.
Are there scientific studies supporting the use of B. infantis?
Yes, extensive clinical studies, including randomized controlled trials, support the efficacy of B. infantis in establishing a healthy infant microbiome. Research consistently demonstrates its role in shaping the infant microbiome, programming immune responses, and reducing inflammatory conditions.
Is B. infantis safe for infants?
B. infantis is generally considered very safe for infants, given its natural presence in a healthy infant gut microbiome. Side effects are are and typically mild, such as temporary minor digestive upset, especially when first introduced.
How much B. infantis should be given to infants, and how often?
Typical infant probiotic formulations contain 1–10 billion CFU (colony-forming units) of B. infantis per dose, though optimal dosing varies by product and age. Most clinical studies in infants used daily dosing, and it is generally safe to give continuously from birth or introduction without cycling on and off. Always follow the product label or pediatrician guidance, as dosage may depend on the infant's age, weight, and specific health condition being addressed.
Can B. infantis be safely used alongside antibiotics in infants?
B. infantis can be used during and after antibiotic courses, as it may help restore healthy gut flora disrupted by antibiotics. However, it is best to administer B. infantis at least 2–3 hours apart from antibiotics to avoid direct antibiotic exposure that could reduce bacterial viability. Consult with a pediatrician before combining B. infantis with any medication to ensure optimal timing and safety.
Which infants benefit most from B. infantis supplementation?
B. infantis is most beneficial for exclusively or predominantly breastfed infants, as they naturally consume HMOs in breast milk that B. infantis uniquely metabolizes. Infants experiencing colic, frequent infections, irregular digestion, or those born via cesarean section (which delays natural microbial colonization) may also see particular benefits. Formula-fed infants can benefit as well, though the advantage may be less pronounced since standard infant formula does not contain HMOs at the same levels as breast milk.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w bifidobacterium-longum-subspecies-infantis curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
